Tissue Diagnostics Market

Tissue Diagnostics Market Outlook 2031

The Tissue Diagnostics Market size was USD 5.19 Billion in 2022 and is likely to reach USD 9.66 Billion by 2031, expanding at a CAGR of 7.15% during 2023–2031. The growth of the market is attributed to increasing government initiative for cancer awareness & health expenditure, rising number of the geriatric populace, and rising number of cancer incidence worldwide.

Tissue diagnosis, also known as histopathology, is a method of extracting tissue from various parts of body and examine in under microscope to analyze manifestations of disease, especially various type of cancer monitoring. According to World Health Organization (WHO), 18.1 million new cancer cases were reported every year including 9.6 million of death due to cancer occurred in 2018.

Get Free Sample Report

Tissue diagnosis refers to analysis of tissue sample by medical professionals. In this process, tissue sample extracted from body and placed onto glass slides for staining by using reagents and dyes for further examination by methods such as biopsy or surgery.

Tissue diagnosis plays a significant role in the diagnosis of DNA sequencing, decode tumour on molecular basis, and spreading tumours. Fine needle aspiration cytopathology along with the open and liquid biopsy are the key methods used for diagnosis of cancer tumour. In general, medical professional differentiate between normal body tissue and cancerous tissue, helping to identify stage and type of cancer.

Tissue Diagnostics Market Trends, Drivers, Restraints, and Opportunities

• Increasing demand for automated histopathological tools and emergence of advanced imaging procedures namely autofluorescence that help to lessen invasive diagnosis are estimated to fuel the market growth.
• Introduction of digital technology assisted tissue diagnosis help to medical professionals to provide finer patient care with precise test results. Rising prevalence of cancer disease, use of personalized drugs, and higher investment in cancer research are the factors anticipated to boost the growth of the market.
• The coronavirus (COVID-19) pandemic is expected to foster market expansion due to rising demand of advance diagnostic tools and testing kits as well as rising healthcare awareness among the people in the upcoming years.
• Requirement for high capital investment in diagnosis equipment, expensive diagnosis treatment, and lack of skilled medical technologist are the major challenging factors estimated to hamper the growth of the market during the forecast period.
• Introduction of automated diagnosis methods, increasing government initiative for cancer awareness, and increasing incidence of cancer are expected to create lucrative opportunities for the market expansion during the forecast period.

Scope of  The Tissue Diagnostics Market Report

The report on the global tissue diagnostics market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Global Tissue Diagnostics Market Segment Insights

Immunohistochemistry is expected to grow at a rapid pace

Based on technology & products, the global tissue diagnostics market is divided into immunohistochemistry, in-situ hybridization, primary & special staining, digital pathology & workflow, and anatomic pathology. The immunohistochemistry segment is further divided into instruments and consumables. The instrument segment is sub-divided into slide staining systems, tissue microarrays, tissue processing systems, slide scanners, and others; while the consumable segment consists of antibodies, reagents, and kits.

On the other hand, the in-situ hybridization segment includes instruments, consumables, and software. The digital pathology & workflow segment is further segregated into whole slide imaging, image analysis informatics, and information management system storage & communication.

Meanwhile, the anatomic pathology segment is further bifurcated into instruments and consumables. The instruments segment includes sub-segments such as microtomes & cryostat microtomes, tissue processors, automatic stainers, and others; whereas, the consumables segment consists of reagents & antibodies, probes & kits, and others.

The immunohistochemistry segment is expected to account for a key share of the market in terms of revenue and estimated to constitute a dominant share of the market in the coming years. Wide use of immunohistochemistry due to its ability to distinguish diverse type of cancer as compared to traditional enzyme staining methods is a key driving factor boosting the segment growth.

However, the digital pathology & workflow segment is anticipated to expand at a rapid pace during the forecast period owing to rising demand of whole slide imaging technology by medical professionals. The development of advanced infrastructure such as a whole slide imaging technique provides accurate results in the diagnosis of cancer tumors and ability to differentiate type and pathology of tumors.

Breast cancer segment constituted a major share

In terms of applications, the global tissue diagnostics market is segmented into breast cancer, non-small cell lung cancer, prostate cancer, gastric cancer, and others. The breast cancer segment accounted for a dominant market share in 2020 and is expected to represent a major share of the market during the forecast period.

Increasing incidence of breast cancer due to genetically transference of disease across the globe and improvement in the efficient breast cancer diagnosis are key driver for the segment growth. Moreover, factors such as rising research collaborations by academic institutions and players as well as development of advanced diagnostic methods for identification and treatment of breast cancer are the factors contributing to propel of segment expansion.

However, the prostate cancer segment is anticipated to register lucrative CAGR during the forecast period due to substantial investment on research by key players for early-stage tumour detection and treatment of disease. Development of biomarkers and human genome project pertaining to histopathological assays are expected to create opportunities for the segment in the upcoming years.

Get Free Sample Report

Hospital segment is holding a dominant market share

On the basis of end-users, the global tissue diagnostics market is segmented into hospitals, research laboratories, pharmaceutical organizations, contract research organizations (CROs). The hospital segment accounted for a dominant market share in 2019 and is expected to register a robust CAGR during the forecast period.

Wide adoption of tissue diagnosis methods which enable precise test results in lesser time period in hospitals as compared to traditional enzyme assays act as key driving factors for the segment. Increase in consumption and utilization rate of tissue diagnosis, and integrated digital diagnostic procedures are the factors that propel the segment growth.

On the other hand, the CROs segment is estimated to witness lucrative expansion during the forecast period, 2023-2031. Contract research organisations enable extensive research, manage candidate molecules during the process of clinical trials, and increase research methodology for prevention of cancer are expected to boost growth in the upcoming years.

Get Free Sample Report

North America accounts for a large market share

In terms of regions, the market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is expected to represent a major market share in terms of revenue generation due to rising research alliances by pharmaceutical and biotechnology companies for prevention & better treatment of disease.

Additionally, the wide establishment of advanced infrastructure of hospitals and clinical pathologies, existence of government initiatives to lessen cancer cases & increasing demand of cancer diagnosis assays, and high prevalence of cancer rate are further fostering the segment augmentation.

On the other hand, the market in Asia Pacific is anticipated to register a robust CAGR during the forecast period due to improvement in good laboratory practice and increasing provision of patient care. Moreover, increase in government initiatives and rising awareness among patients are expected to bolster the segment growth in the region during the upcoming years from 2023-2031.

Get Free Sample Report

Segments

The global tissue diagnosis market has been segmented on the basis of

Technology & Products

• Immunohistochemistry
  • Instruments
    • Slide Staining Systems
    • Tissue Microarrays
    • Tissue Processing Systems
    • Slide Scanners
    • Others
  • Consumables
    • Antibodies
    • Reagents
    • Kits
• In-Situ Hybridization
  • Instruments
  • Consumables
  • Software
• Primary & Special Staining
• Digital Pathology & Workflow
  • Whole Slide Imaging
  • Image Analysis Informatics
  • Information Management System Storage & Communication
• Anatomic Pathology
  • Instruments
    • Microtomes & Cryostat Microtomes
    • Tissue Processors
    • Automatic Stainers
    • Others
  • Consumables
    • Reagents & Antibodies
    • Probes & Kits
    • Others

Applications

• Breast Cancer
• Non-small Cell Lung Cancer
• Prostate Cancer
• Gastric Cancer
• Others

End-Users

• Hospitals
• Research Laboratories
• Pharmaceutical Organizations
• Contract Research Organizations [CROs]

Regions

• Asia Pacific
• North America
• Latin America
• Europe
• Middle East & Africa

Key Players

• F. Hoffmann-La Roche Ltd
• Thermo Fisher Scientific
• Abbott Laboratories Inc.
• Siemens Healthcare AG
• Agilent Technologies Inc.
• Danaher Corporation
• BioMerieux SA
• Sekisui Diagnostics LLC
• BioMedica Diagnostics LLC
• Becton, Dickinson & Company
• Cell Signalling Technology Inc.
• BioGenex Laboratories
• Helena Biosciences
• Quidel Corporation
• Sakura Finetek Japan Co. Ltd.

Competitive Landscape

Some of the key players competing in the market are F. Hoffmann-La Roche Ltd; Thermo Fisher Scientific; Abbott Laboratories Inc.; Siemens Healthcare AG; Agilent Technologies Inc.; Danaher Corporation; BioMerieux SA; Sekisui Diagnostics LLC; BioMedica Diagnostics LLC; Becton, Dickinson & Company; Cell Signalling Technology Inc.; BioGenex Laboratories; Helena Biosciences; Quidel Corporation; and Sakura Finetek Japan Co. Ltd.

Many of these key players are actively investing in research & development to develop new technologies. Additionally, they are also actively engaged in various market strategies such as product launches, mergers, partnerships, acquisitions, and expansion of production units to enhance their market position and expand their consumer base across the globe.

In January 2018, Roche introduced a software that offered lessen imaging time, precise test results, and descriptive analysis of digital diagnosis. In July 2018, it also launched antibodies and advanced staining process that readily differentiated the identification of cancer type.